Beruflich Dokumente
Kultur Dokumente
HIV/AIDS medication
Cipla is the world's largest manufacturer of antiretroviral drugs[23] (ARVs) to fight
HIV/AIDS, as measured by units produced and distributed. Roughly 40 percent of HIV/AIDS
patients undergoing antiretroviral therapy worldwide take Cipla drugs.[24][25]
From 1972 until 2005 Indian law did not allow product patents on drugs. As a result, Cipla
was able to manufacture medicines which enjoyed patent monopoly in other countries.
Cipla also pioneered a three-in-one tablet called Triomune containing a fixed-dose
combination (FDC) of three ARVs (Lamivudine, stavudine and Nevirapine), something
difficult elsewhere because the three patents were held by different companies. Another
popular fixed-dose combination is produced under the name Duovir-N. This contains
Lamivudine, Zidovudine and Nevirapine. Cipla manufactures generic versions of many of the
most commonly prescribed anti-retroviral medication in the market,[26] and is a highly capable
manufacturer in its own right. This innovation made ARVs far more accessible and easy-totake for patients everywhere, but particularly in poor- and middle-income countries, where
the vast majority of people on anti-retroviral therapy (ART) now take such combination pills.
Cipla was among the first companies to register AIDS drugs under the US relief program
PEPFAR.[27] It has also been a major supplier of ARVs to the Clinton Foundation's HIV/AIDS
Initiative, which has negotiated low-cost drug supplies for numerous developing countries.
Cipla has played an important role in fighting HIV/AIDS in Africa and other developing
countries through its price offers to leading NGOs such as Doctors Without Borders and
Oxfam, and with its keen participation in PEPFAR, the Global Fund, the Clinton Foundation's
HIV/AIDS Initiative.[28]
CIPLA
Type
Traded as
Public
BSE: 500087
NSE: CIPLA
BSE SENSEX Constituent
CNX Nifty Constituent
Industry
Pharmaceuticals
Founded
1935
Founder
Dr. K. A. Hamied
Headquarters
Mumbai, Maharashtra, India
Area served
Worldwide
Y. K. Hamied, Chairman
Key people
Subhanu Saxena (CEO)
Products
Pharmaceuticals and diagnostics
104.83 billion
Revenue
(US$1.6 billion) (2013-14)[1]
18.80 billion
Operating income
(US$300 million) (2012-13)[1]
13.89 billion
Net income
(US$220 million) (2013-14)[1]
109.68 billion
Total assets
(US$1.7 billion) (2013-14)[1]
100.91 billion
Total equity
(US$1.6 billion) (2013-14)[1]
Number of
22,036[2]
employees